Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

191
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
191
Inflammation01:38

Inflammation

62.3K
Overview
62.3K
Decreasing Function01:27

Decreasing Function

303
A decreasing function describes a relationship where the output consistently declines as the input increases. This means that for any two input values, if one is greater than the other, the corresponding output is smaller. Mathematically, a function f is decreasing on an interval I if for every x1 < x2​ in I, f (x1) > f (x2). This type of behavior is visually identified on a graph that slopes downward from left to right.The nature of a function can be analyzed by calculating...
303
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

207
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
207
Obesity01:24

Obesity

1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

234
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cellular intermediates unveils unique enzymes for flagellar glycan biosynthesis in <i>Clostridioides difficile</i>.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Economic impact of disposable versus reusable instruments in minimally invasive surgery: a systematic review.

Surgical endoscopy·2026
Same author

Diversion of Arginine's dietary metabolic fate in proteinuric kidney disease.

Research square·2026
Same author

Interleukin-6 stimulates platelet 12-lipoxygenase to drive coagulation in inflammatory arthritis.

Journal of lipid research·2026
Same author

Comprehensive Lipidomic Profiling Reveals Distinct Metabolic Remodeling during Differentiation of Human Monocyte-Derived Macrophages.

Journal of proteome research·2026
Same author

Longitudinal analysis of lipid changes in the sciatic nerve caused by overexpression of PMP22 in murine models of CMT1A.

Journal of lipid research·2026

Related Experiment Video

Updated: Feb 9, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

26.0K

Metabolic liver inflammation in obesity does not robustly decrease hepatic and circulating CETP.

Lisanne L Blauw1, Zhuang Li2, Sander S Rensen3

  • 1Dept. Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Dept. Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Atherosclerosis
|June 15, 2018
PubMed
Summary

Metabolic liver inflammation in obese individuals did not significantly decrease cholesteryl ester transfer protein (CETP) levels, unlike lipopolysaccharide (LPS) activation of Kupffer cells. This suggests inflammation

Keywords:
CETPLipid metabolismLiver inflammationObesity

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.7K

Related Experiment Videos

Last Updated: Feb 9, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

26.0K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.7K

Area of Science:

  • Hepatology
  • Metabolic disease research
  • Immunology

Background:

  • Plasma cholesteryl ester transfer protein (CETP) is primarily produced by Kupffer cells, which are liver-resident macrophages.
  • Activation of Kupffer cells by lipopolysaccharide (LPS) significantly reduces CETP expression.
  • Kupffer cell activation is implicated in the progression of non-alcoholic fatty liver disease (NAFLD).

Purpose of the Study:

  • To investigate the association between metabolic liver inflammation and CETP expression and concentration in obese individuals.
  • To determine if liver inflammation mirrors the strong CETP-reducing effects of LPS on Kupffer cells.

Main Methods:

  • Collection of plasma and liver biopsy samples from 93 obese individuals undergoing bariatric surgery.
  • Histological assessment of liver lobular inflammation.
  • Quantification of hepatic CETP expression, CETP-positive cells, plasma CETP concentrations, and hepatic VSIG4 expression.

Main Results:

  • No strong negative association was found between liver inflammation and hepatic CETP expression, CETP-positive cells, or plasma CETP concentrations.
  • A trend towards decreased plasma CETP was observed in the presence of liver inflammation.
  • Hepatic VSIG4 expression showed no association with liver inflammation.

Conclusions:

  • Metabolic liver inflammation in obese individuals does not appear to significantly reduce hepatic or circulating CETP levels.
  • The effects of metabolic liver inflammation on CETP are less pronounced than those of LPS-induced Kupffer cell activation.
  • These findings differentiate the impact of metabolic inflammation from endotoxin-driven immune responses on CETP homeostasis.